30results about How to "Inhibit cell migration" patented technology

The invention is a template to aid in the regeneration of articular cartilage. The template is formed by combining a porous collagen sponge ("collagen matrix") with a dense collagen membrane. The dense collagen membrane is placed on the surface of the cartilage defect to prevent cell migration from the subchondral plate and vasculature. The collagen membrane will allow movement and exchange of fluids, nutrients, cytokines and other factors necessary for cartilage regeneration. The collagen matrix has been developed to allow attachment and growth of cells, specifically chondrocytes which are normally found in articular cartilage. The collagen matrix can be combined with chondrocytes in vitro, and therefore serve to transport cultured cells to the defect site and to retain the cells in position following implantation. Procedures are described to effectively use the two-staged template, and to fix the template to the repair site.

The invention concerns an endovascular implant for the application of an active substance into the media 22 of a blood vessel and two processes for the production thereof. A base body 42 of the implant has at least in portion-wise manner at a surface 40 which is towards the blood vessel, a plurality of microdevices 10 for injection of the active substance. Each microdevice 10 includes on the one hand at least one microcannula 38 which is raised out of the surface 40 of the implant to such an extent that, when the implant bears against a wall 12 of the blood vessel in surface contact, the microcannula penetrates into the media 22 of the blood vessel, and on the other hand at least one active substance deposit 36 which is in communication with at least one microcannula 38.

Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis.

Though copper is elevated in the tumor tissue and plasma of patients with various malignancies, the molecular targets for copper binding agents in angiogenesis and tumor progression remain poorly understood. It is disclosed that one anti-angiogenic target for the copper binding agent tetrathiomolybdate is intracellular CuZn-superoxide dismutase (SOD1). A second generation tetrathiomolybdate analog, ATN-224, inhibits endothelial cell (EC) proliferation in vitro, binds to SOD1 and inhibits its activity without displacing bound copper ATN-224 can accumulate in ECs and inhibit CuZnSOD activity with an IC₅₀ similar to the IC₅₀ for EC proliferation, resulting in increased generation of intracellular reactive oxygen species. Inhibition of EC proliferation by ATN-224 in vitro is substantially reversed by a synthetic porphyrin SOD mimetic. Similar results were observed in vivo, where inhibition of angiogenesis by ATN-224 in a Matrigel plug model was also reversed by MnTBAP. Thus, a distinct molecular target for copper depletion therapy has been identified and SOD1 is now validated as a target for anti-angiogenesis. Methods for screening, or designing, such SOD1 inhibitors for use as angiogenesis inhibitors and anti-cancer agents are disclosed.

The invention relates to endostatin, protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.

Methods are disclosed for promoting wound repair, by magnetically retaining or confining stem cells, or other cells capable of generating the desired tissue, in a target region (e.g., a wound) where tissue regrowth is needed. Also disclosed are magnetic particles and magnetically inducible particles for these methods, as well as sheets comprising magnetic materials.

The present invention provides a semi-crystalline polymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.

An object of the present invention is to provide a method for inducing differentiation and/or promoting proliferation of regulatory T cells, a method for suppressing the transendothelial cell migration of immunocytes, a method for suppressing immunity using these methods, and a pharmaceutical composition to be used for these methods. Provided are a method for inducing differentiation and/or promoting proliferation of regulatory T cells by causing CD52 agonists, including anti-CD52 antibodies, to act on CD52-expressing T cells, a method for suppressing the transendothelial cell migration of immunocytes, and a method for suppressing immunity using these methods.

The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors.

This invention provides an isolated polypeptide comprising all or a portion of the c-terminal domain of EB1, wherein the isolated polypeptide does not consist of residues 150-268, 219-268 or 185-268 of SEQ. ID. NO:2. This invention further provides related compositions, nucleic acids, cells and methods.

An intraocular lens implantable in an eye includes an optic for placement in the capsular bag of the eye and for directing light toward the eye's retina. The optic has a central optical axis, an anterior surface, an opposing posterior surface and optic peripheral edge surface between the surfaces. The peripheral edge includes regions of a substantially continuous configuration with radii are such that their optical centers either within the optic or outside the optic and also being substantially smaller the radius of the optic of equivalent dimension but circular shape of substantially constant radius. The peripheral edge surface has a substantially flat configuration in the direction between the surfaces. The intersection of the peripheral edge surface and at least one of the anterior surface and the posterior surface, forms a discontinuous sharp corner edge.

A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation.

The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.

The invention relates to the technical field of molecular biology and tumor marker medicine, in particular to application of an IGFL4 gene as a marker in diagnosis and treatment of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer. The IGFL4 gene can be used as a diagnostic biomarker for gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer or can be used for preparing a cancer diagnosis product. The IGFL4 gene is specifically overexpressed in gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, but there is no such specific high expression in normal tissues. By detecting IGFL4 gene expression in a subject, occurrence of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer can be quickly, accurately and clearly determined. The IGFL4 gene serves as a diagnostic marker of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, provides a new target for clinical treatment of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, and can be applied to preparation of antitumor drugs.

Provided are extracellular matrix protein 1 (ECM1) and fusion protein Fc-ECM1 of the ECM1 and the Fc sequence, and also provided are cloning construction and expression of the protein, and use of the protein in preparing a pharmaceutical composition for treating multiple sclerosis.

The inventive is directed to a haptic for fixation to, and manufacture in conjunction with, an intraocular lens to be implanted in the natural lens capsule of the human eye. The haptic secures the lens in an appropriate position within the natural capsule so as to provide optimal visual acuity through the aphakic lens. The haptic ends are designed to position the lens neutrally, anteriorly or posteriorly within the lens envelope. At the connection point of the ribbon portion to the solid end plate of the haptic, the haptic may be notched to facilitate compressing the lens into its injector for insertion into the eye through an incision in the cornea. Once compressed and passed through the cornea, the implanted lens will be secured by the haptics in the lens capsule once all possible natural lens material and epithelial cells have been removed.

Methods for classifying, identifying and monitoring of a medulloblastoma tumor in a subject are provided, based on lincRNA expression in the tumor and/or in a biological sample of the subject. Compositions and methods for treating medulloblastoma using inhibitors of the specific lincRNAs disclosed herein. Additionally, novel inhibitory nucleic acids targeting the specific lincRNAs are provided.

The invention relates to the technical field of molecular biology and tumor marker medicine, in particular to application of a KLC3 gene as a marker in diagnosis and treatment of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer. The KLC3 gene can be used as a diagnostic biomarker for lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer or can be used for preparing a cancer diagnosis product. The KLC3 gene is specifically overexpressed in lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, but there is no such specific high expression in normal tissues. By detecting the expression of the KLC3 gene in a subject, the occurrence of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer can be quickly, accurately and clearly determined. The KLC3 gene serves as a diagnostic marker of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, provides a new target for clinical treatment of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, and can be applied to preparation of antitumor drugs.

The present invention relates to methods and compositions for modulating ADPR-mediated migratory activity of cells through regulation of the TRPM2 cation channel. Such methods and compositions may be used for the treatment of disorders including, but not limited to, inflammation, ischemia, atherosclerosis, asthma, autoimmune disease, diabetes, arthritis, allergies, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages, monocytes and dendritic cells. The invention further relates to specific inhibition of TRPM2 by blocking the activity of ADPR. The invention also relates to drug screening assays designed to identify compounds that regulate TRPM2 and thereby also function to modulate ADPR-mediated cell migration. The invention is based on the discovery that, 8Br-ADPR, which specifically inhibits activation of TRPM2, acts to inhibit ADPR-mediated cell migration.

Aptamers identified capable of binding glioblastoma cells, and their use in methods of medical treatment and prophylaxis are disclosed.